CAR-T– tag –
-
Chinese Scientists Achieve Breakthrough: Mass Production of 14 Million NK Immune Cells from a Single Stem Cell, Paving Way for ‘Off-the-Shelf’ Immunotherapy
Facebook (referencing a February 2026 breakthrough in China) China Overview In February 2026, Chinese scientists announced a breakthrough, successfully mass-producing an astounding 14 million natural killer (NK) immune cells in the lab f... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra... -
Liv Hospital Details Advanced ‘Off-the-Shelf’ CAR-T Manufacturing, Promising Scalability and Broader Access
Liv Hospital Turkey Overview Liv Hospital has unveiled its detailed manufacturing process for allogeneic, 'off-the-shelf' CAR-T cell therapy, a significant leap towards overcoming the logistical and cost barriers of current personalized ... -
NueCell Bio Unveils 26,300 Sq Ft Cell Therapy Development Facility in San Diego, Bolstering Clinical & Commercial Manufacturing
PharmaSource USA Overview NueCell Bio has officially opened its 26,300-square-foot cell therapy development facility in San Diego, significantly enhancing its clinical and commercial manufacturing capabilities. The state-of-the-art facil... -
Texas Children’s Hospital’s GMP Facility Manufactures Over 10,000 Cell Therapy Products in 20 Years, Driving CGT Innovation
Texas Children's Hospital USA Overview Texas Children's Hospital's Center for Cell and Gene Therapy (CAGT) has manufactured over 10,000 cell therapy products and more than 70 clinical-grade viral vectors over two decades, utilizing its i... -
In Vivo CAR T-Cell Therapy KLN-1010 Achieves 100% MRD Negativity in Multiple Myeloma Phase 1 Trial, Presented at ASCO/EHA 2026
International Myeloma Foundation USA Overview At the 2026 ASCO and EHA meetings, groundbreaking results for KLN-1010, an in vivo CAR T-cell therapy eliminating the need for ex vivo T-cell harvest, were highlighted. The clinical trial in ... -
Single-Day Manufactured IL-18-Armed CAR T Cells Demonstrate Durable Anti-Tumor Efficacy and Exhaustion Resistance
Blood - ASH Publications USA Overview Researchers have developed a novel single-day manufacturing process for nonactivated IL-18-armed CAR T cells, exhibiting potent anti-tumor efficacy and enhanced persistence in both in vitro and in vi... -
Precision and Pace: Liv Hospital Details Step-by-Step Innovations in CAR-T Cell Manufacturing
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive, step-by-step guide to CAR-T cell manufacturing, spanning the entire process from leukapheresis to final formulation. The blueprint emphasizes stringent quality contr...
